Phaseline

Targets › PVRL2

PVRL2 (Nectin-2): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Oncology; next expected readout Dec 2026.

Modulator of T-cell signaling. Can be either a costimulator of T-cell function, or a coinhibitor, depending on the receptor it binds to. (UniProt, Q92692)

Open in Phaseline: the race on PVRL2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Hebei Medical University Fourth HospitalTuvonralimab
PVRL2 (CD112R) inhibitor
PVRL2Phase 2Esophageal Squamous Cell Carcinoma (ESCC)Dec 2026

Conditions

Esophageal Squamous Cell Carcinoma (ESCC) (1)

Modalities

–

Companies

Hebei Medical University Fourth Hospital (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.